Helping those who cannot afford costly branded medicines has always been on the Ind-Swift agenda and the Generics division provides the same active ingredients as their branded equivalents. The Generics division is further divided into Agile, Maxcare and Health Care divisions. The portfolio of these divisions includes an assortment of over 500 products from various therapeutic segments namely Antibiotic, Anti-Infectives, Anti-Cold, Nutraceuticals, Anti-Convulsants, Analgesics, Anti-Diarrhoeal, Anti-Allergics, Anti-Inflammatory and Anti-Ulcer Drugs, Hypolipidaemic Drugs, Anti Malarial, Enzyme, Expectorants, Antipsychotics & Anti-Depressants.
In July 2011, FDA began a pilot program to notify people of drug recalls before they are classified in an effort to expedite notifications of human drug product recalls to the public. FDA is now able to accomplish the goal of expedited notification within the Enforcement Report. These recalls are identified within the Enforcement Report by the label of “Not Yet Classified” in the “Classification” column. It is also possible to search the Enforcement Report for these “Not Yet Classified” recalls using the filter drop down menu. Therefore, as of September 15, 2017 FDA will discontinue the pilot program, and will no longer post drug recalls that are pending classification on this webpage. To see posted recalls that are pending classification go to the weekly Enforcement Report.